Rekah Pharmaceutical Industry Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was ILS 79.96 million compared to ILS 73.41 million a year ago. Net loss was ILS 5.49 million compared to net income of ILS 0.365 million a year ago. Basic loss per share from continuing operations was ILS 0.48 compared to basic earnings per share from continuing operations of ILS 0.03 a year ago. Diluted loss per share from continuing operations was ILS 0.48.
For the nine months, sales was ILS 235.62 million compared to ILS 212.72 million a year ago. Net loss was ILS 6.01 million compared to net income of ILS 0.387 million a year ago. Basic loss per share from continuing operations was ILS 0.53 compared to basic earnings per share from continuing operations of ILS 0.03 a year ago.